Cara Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
Janney Cuts Price Target on Cara Therapeutics (CARA) as UP is Delayed
March 11, 2016 10:12 AM ESTJanney Capital maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA), and cut the price target to $18.00 (from $23.00), following the company's 4Q earnings report and conference call. The most significant development on the call was the disclosure that its December 2015 meeting with the FDA regarding its effort to develop CR845 for UP. Janney thought... More
